mammon hamid, partner at kleiner perkins. coming up, we will be talking about a new potential for a vaccine going into phase one clinical trials. we will talk to the guy known as the father of dna vaccines about the progress and any issues so far. we will take you to the rose garden as soon as the coronavirus task force briefing begins. ♪ the biotech firm in novi is second to test his covid-19 candidate on humans. trials started next week. we spoke to dr. david weiner about how the trials going so far. david: there are no issues. are two dose groups, a one milligram and two milligram. one milligram is being done now and then we will go to the two milligrams. emily: you are known as the father of dna vaccines. why do you think the dna approach is the right approach? david: the approaches such as we are using and some other groups are using it's really have significant advantages. it took us about 10 weeks to get into the clinic. a lot of animals along the way. it has a very reproducible manufactory temperature-stable. it is si